Blockade of CXCR2 signalling: A potential therapeutic target for preventing neutrophil-mediated inflammatory diseases

Experimental Biology and Medicine

Volumn 239, Issue 5, 2014, Pages 509-518

  Boppana, Nithin B ^a   Devarajan, Asokan ^b   Gopal, Kaliappan ^c   Barathan, Muttiah ^c   Bakar, Sazaly A ^c   Shankar, Esaki M ^c   Ebrahim, Abdul S ^d   Farooq, Shukkur M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemokine analogs; CXCR2 antagonists; integrins; neutrophil infiltration; PMN; selectins; transmigration

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL) UREA; 1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; AMINOSALICYLIC ACID; ANGIOTENSIN II; AZ 10397767; AZD 8309; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; DANIRIXIN; DIACYLGLYCEROL; ELUBRIXIN; G PROTEIN COUPLED RECEPTOR; INDOMETACIN; INOSITOL 1, 4, 5 TRISPHOSPHATE; INTERLEUKIN 8; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE; PHOSPHOLIPASE C; PROTEIN KINASE C; PYRIMIDINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REPARIXIN; ROLIPRAM; SB 265610; SB 332235; SB 468477; SKF 83589; SODIUM PROTON EXCHANGE PROTEIN 1; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; BIOAVAILABILITY; BRAIN ISCHEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLITIS; HUMAN; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; INNATE IMMUNITY; INTRACELLULAR SIGNALING; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PSORIASIS; RECEPTOR BLOCKING; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; STOMACH MUCOSA LESION;

CHEMOKINE ANALOGS; CXCR2 ANTAGONISTS; INTEGRINS; NEUTROPHIL INFILTRATION; PMN; SELECTINS; TRANSMIGRATION;

ANIMALS; CELL MOVEMENT; HUMANS; INFLAMMATION; NEUTROPHILS; RECEPTORS, INTERLEUKIN-8B; SIGNAL TRANSDUCTION;

EID: 84899680287     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213520110     Document Type: Review

References (98)

1. Muller WA.Getting leukocytes to the site of inflammation.Vet Pathol. 2013;50:7-22.
2. Ley K,Laudanna C,Cybulsky MI,Nourshargh S.Getting to the site of inflammation: the leukocyte adhesion cascade updated.Nat Rev Immunol. 2007;7:678-89.
3. Sanz MJ,Kubes P.Neutrophil-active chemokines in in vivo imaging of neutrophil trafficking.Eur J Immunol. 2012;42:278-83.
4. Singh JK,Simoes BM,Howell SJ,Farnie G,Clarke RB.Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells.Breast Cancer Res. 2013;15:210-210.
5. Min SH,Wang Y,Gonsiorek W,Anilkumar G,Kozlowski J,Lundell D,Fine JS,Grant EP.Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis.Biochem Biophys Res Commun. 2010;391:1080-6.
6. Barsante MM,Cunha TM,Allegretti M,Cattani F,Policani F,Bizzarri C,Tafuri WL,Poole S,Cunha FQ,Bertini R,Teixeira MM.Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats.Br J Pharmacol. 2008;153:992-1002.
7. Farooq SM,Stillie R,Svensson M,Svanborg C,Strieter RM,Stadnyk AW.Therapeutic effect of blocking CXCR2 on neutrophil recruitment and dextran sodium sulfate-induced colitis.J Pharmacol Exp Ther. 2009;329:123-9.
8. Williams EJ,Haque S,Banks C,Johnson P,Sarsfield P,Sheron N.Distribution of the interleukin-8 receptors, CXCR1 and CXCR2, in inflamed gut tissue.J Pathol. 2000;192:533-9.
9. Bizzarri C,Beccari AR,Bertini R,Cavicchia MR,Giorgini S,Allegretti M.ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.Pharmacol Ther. 2006;112:139-49.
10. Stillie R,Farooq SM,Gordon JR,Stadnyk AW.The functional significance behind expressing two IL-8 receptor types on PMN.J Leukocyte Biol. 2009;86:529-43.
11. Marsh DR,Flemming JM.Inhibition of CXCR1 and CXCR2 chemokine receptors attenuates acute inflammation, preserves gray matter and diminishes autonomic dysreflexia after spinal cord injury.Spinal Cord. 2011;49:337-44.
12. Lloyd A,Modi W,Sprenger H,Cevario S,Oppenheim J,Kelvin D.Assignment of genes for interleukin-8 receptors (IL8R) A and B to human chromosome band 2q35.Cytogenet Cell Genet. 1993;63:238-40.
13. Sprenger H,Lloyd AR,Meyer RG,Johnston JA,Kelvin DJ.Genomic structure, characterization, and identification of the promoter of the human IL-8 receptor A gene.J Immunol. 1994;153:2524-32.
14. Murphy PM,Tiffany HL.Cloning of complementary DNA encoding a functional human interleukin-8 receptor.Science. 1991;253:1280-3.
15. Sprenger H,Lloyd AR,Lautens LL,Bonner TI,Kelvin DJ.Structure, genomic organization, and expression of the human interleukin-8 receptor B gene.J Biol Chem. 1994;269:11065-72.
16. Lee J,Horuk R,Rice GC,Bennett GL,Camerato T,Wood WI.Characterization of two high affinity human interleukin-8 receptors.J Biol Chem. 1992;267:16283-7.
17. Cerretti DP,Kozlosky CJ,Vanden Bos T,Nelson N,Gearing DP,Beckmann MP.Molecular characterization of receptors for human interleukin-8, GRO/melanoma growth-stimulatory activity and neutrophil activating peptide-2.Mol Immunol. 1993;30:359-67.
18. Weathington NM,van Houwelingen AH,Noerager BD,Jackson PL,Kraneveld AD,Galin FS,Folkerts G,Nijkamp FP,Blalock JE.A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation.Nat Med. 2006;12:317-23.
19. Clarke C,Kuboki S,Sakai N,Kasten KR,Tevar AD,Schuster R,Blanchard J,Caldwell CC,Edwards MJ,Lentsch AB.CXC chemokine receptor-1 is expressed by hepatocytes and regulates liver recovery after hepatic ischemia/reperfusion injury.Hepatology. 2011;53:261-71.
20. Shamaladevi N,Lyn DA,Escudero DO,Lokeshwar BL.CXC receptor-1 silencing inhibits androgen-independent prostate cancer.Cancer Res. 2009;69:8265-74.
21. Hartl D,Latzin P,Hordijk P,Marcos V,Rudolph C,Woischnik M,Krauss-Etschmann S,Koller B,Reinhardt D,Roscher AA,Roos D,Griese M.Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease.Nat Med. 2007;13:1423-30.
22. Juremalm M,Nilsson G.Chemokine receptor expression by mast cells.Chem Immunol Allergy. 2005;87:130-44.
23. Sharma B,Nawandar DM,Nannuru KC,Varney ML,Singh RK.Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis.Mol Cancer Ther. 2013;12:799-808.
24. Veenstra M,Ransohoff RM.Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?.J Neuroimmunol. 2012;246:1-9.
25. Zhang ZJ,Cao DL,Zhang X,Ji RR,Gao YJ.Chemokine contribution to neuropathic pain: Respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons.Pain. 2013;154:2185-97.
26. Svensson M,Irjala H,Svanborg C,Godaly G.Effects of epithelial and neutrophil CXCR2 on innate immunity and resistance to kidney infection.Kidney Int. 2008;74:81-90.
27. Whittall C,Kehoe O,King S,Rot A,Patterson A,Middleton J.A chemokine self-presentation mechanism involving formation of endothelial surface microstructures.J Immunol. 2013;190:1725-36.
28. Kaur M,Singh D.Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.J Pharmacol Exp Ther. 2013;347:173-80.
29. Weinger JG,Marro BS,Hosking MP,Lane TE.The chemokine receptor CXCR2 and coronavirus-induced neurologic disease.Virology. 2013;435:110-7.
30. Raccosta L,Fontana R,Maggioni D,Lanterna C,Villablanca EJ,Paniccia A,Musumeci E,Chiricozzi E,Trincavelli ML,Daniele S,Martini C,Gustafsson JA,Doglioni C,Feo SG,Leiva A,Ciampa MG,Mauri L,Sensi C,Prinetti A,Eberini I,Mora MR,Bordignon C,Steffensen KR,Sonnino S,Sozzani S,Traversari C,Russo V.The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils.J Exp Med. 2013;210:1711-28.
31. Ravindran A,Sawant KV,Sarmiento J,Navarro J,Rajarathnam K.Chemokine CXCL1 dimer is a potent agonist for the CXCR2 receptor.J Biol Chem. 2013;288:12244-52.
32. Ghasemzadeh M,Kaplan ZS,Alwis I,Schoenwaelder SM,Ashworth KJ,Westein E,Hosseini E,Salem HH,Slattery R,McColl SR,Hickey MJ,Ruggeri ZM,Yuan Y,Jackson SP.The CXCR1/2 ligand NAP-2 promotes directed intravascular leukocyte migration through platelet thrombi.Blood. 2013;121:4555-66.
33. Johnston RA,Mizgerd JP,Shore SA.CXCR2 is essential for maximal neutrophil recruitment and methacholine responsiveness after ozone exposure.Am J Physiol Lung Cell Mol Physiol. 2005;288:L61-7.
34. Ley K,Laudanna C,Cybulsky MI,Nourshargh S.Getting to the site of inflammation: the leukocyte adhesion cascade updated.Nat Rev Immunol. 2007;7:678-89.
35. Stadtmann A,Zarbock A.CXCR2: From bench to bedside.Front Immunol. 2012;3:263-263.
36. Gao Z,Metz WA.Unraveling the chemistry of chemokine receptor ligands.Chem Rev. 2003;103:3733-52.
37. Schwarz MK,Wells TN.New therapeutics that modulate chemokine networks.Nat Rev Drug Discovery. 2002;1:347-58.
38. Moriconi A,Cesta MC,Cervellera MN,Aramini A,Coniglio S,Colagioia S,Beccari AR,Bizzarri C,Cavicchia MR,Locati M,Galliera E,Di Benedetto P,Vigilante P,Bertini R,Allegretti M.Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.J Med Chem. 2007;50:3984-4002.
39. Auten RL,Richardson RM,White JR,Mason SN,Vozzelli MA,Whorton MH.Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats.J Pharmacol Exp Ther. 2001;299:90-5.
40. Braber S,Overbeek SA,Koelink PJ,Henricks PA,Zaman GJ,Garssen J,Kraneveld AD,Folkerts G.CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1.Eur J Pharmacol. 2011;668:443-9.
41. Kaur M,Singh D.Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.J Pharmacol Exp Ther. 2013;347:173-80.
42. Nie H,Widdowson KL,Palovich MR,Fu W,Elliott JD,Bryan DL,Bryan DL,Burman M,Schmidt DB,Foley JJ,Sarau HM,Busch-Petersen J.N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.Bioorganic Med Chem Lett. 2006;16:5513-6.
43. Chapman RW,Phillips JE,Hipkin RW,Curran AK,Lundell D,Fine JS.CXCR2 antagonists for the treatment of pulmonary disease.Pharmacol Ther. 2009;121:55-68.
44. Virtala R,Ekman AK,Jansson L,Westin U,Cardell LO.Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor.Clin Exp Allergy: J Br Soc Allergy Clin Immunol. 2012;42:590-6.
45. Cutshall NS,Ursino R,Kucera KA,Latham J,Ihle NC.Nicotinamide N-oxides as CXCR2 antagonists.Bioorganic Med Chem Lett. 2001;11:1951-4.
46. Cutshall NS,Kucera KA,Ursino R,Latham J,Ihle NC.Nicotinanilides as inhibitors of neutrophil chemotaxis.Bioorganic Med Chem Lett. 2002;12:1517-20.
47. Bertini R,Allegretti M,Bizzarri C,Moriconi A,Locati M,Zampella G,Cervellera MN,Di Cioccio V,Cesta MC,Galliera E,Martinez FO,Di Bitondo R,Troiani G,Sabbatini V,D'Anniballe G,Anacardio R,Cutrin JC,Cavalieri B,Mainiero F,Strippoli R,Villa P,Di Girolamo M,Martin F,Gentile M,Santoni AD,Corda D,Poli G.Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.Proc Natl Acad Sci U S A. 2004;101:11791-6.
48. Cunha TM,Barsante MM,Guerrero AT,Verri WA,Ferreira SH,Coelho FM,Bertini R,Di Giacinto C,Allegretti M,Cunha FQ,Teixeira MM.Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice.Br J Pharmacol. 2008;154:460-70.
49. Konrad FM,Reutershan J.CXCR2 in acute lung injury.Mediators Inflammation. 2012;2012:740987-740987.
50. Chapman RW,Minnicozzi M,Celly CS,Phillips JE,Kung TT,Hipkin RW,Fan X,Rindgen D,Deno G,Bond R,Gonsiorek W,Billah MM,Fine JS,Hey JA.A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.J Pharmacol Exp Ther. 2007;322:486-93.
51. Ho KK,Auld DS,Bohnstedt AC,Conti P,Dokter W,Erickson S,Feng D,Inglese J,Kingsbury C,Kultgen SG,Liu RQ,Masterson CM,Ohlmeyer M,Rong Y,Rooseboom M,Roughton A,Samama P,Smit MJ,Son E,van der Louw J,Vogel G,Webb M,Wijkmans J,You M.Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists.Bioorganic Med Chem Lett. 2006;16:2724-8.
52. Weidner-Wells MA,Henninger TC,Fraga-Spano SA,Boggs CM,Matheis M,Ritchie DM,Argentieri DC,Wachter MP,Hlasta DJ.Synthesis and structure-activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleukin-8 (IL-8) receptor antagonists.Bioorganic Med Chem Lett. 2004;14:4307-11.
53. Bizzarri C,Pagliei S,Brandolini L,Mascagni P,Caselli G,Transidico P,Sozzani S,Bertini R.Selective inhibition of interleukin-8-induced neutrophil chemotaxis by ketoprofen isomers.Biochem Pharmacol. 2001;61:1429-37.
54. Li F,Zhang X,Mizzi C,Gordon JR.CXCL8((3-73))K11R/G31P antagonizes the neutrophil chemoattractants present in pasteurellosis and mastitis lesions and abrogates neutrophil influx into intradermal endotoxin challenge sites in vivo.Vet Immunol Immunopathol. 2002;90:65-77.
55. Thatcher TH,McHugh NA,Egan RW,Chapman RW,Hey JA,Turner CK,Redonnet MR,Seweryniak KE,Sime PJ,Phipps RP.Role of CXCR2 in cigarette smoke-induced lung inflammation.Am J Physiol Lung Cell Mol Physiol. 2005;289:L322-8.
56. Londhe VA,Belperio JA,Keane MP,Burdick MD,Xue YY,Strieter RM.CXCR2 is critical for dsRNA-induced lung injury: relevance to viral lung infection.J Inflamm (Lond). 2005;2:4-4.
57. Herbold W,Maus R,Hahn I,Ding N,Srivastava M,Christman JW,Mack M,Reutershan J,Briles DE,Paton JC,Winter C,Welte T,Maus UA.Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage recruitment in response to pneumococcal lung infection.Infection Immunity. 2010;78:2620-30.
58. Tsai WC,Strieter RM,Mehrad B,Newstead MW,Zeng X,Standiford TJ.CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia.Infection Immunity. 2000;68:4289-96.
59. Moore TA,Newstead MW,Strieter RM,Mehrad B,Beaman BL,Standiford TJ.Bacterial clearance and survival are dependent on CXC chemokine receptor-2 ligands in a murine model of pulmonary Nocardia asteroides infection.J Immunol. 2000;164:908-15.
60. Mackay CR.Chemokines: immunology's high impact factors.Nat Immunol. 2001;2:95-101.
61. Papadakis KA.Chemokines in inflammatory bowel disease.Curr Allergy Asthma Rep. 2004;4:83-9.
62. Parenty G,Appelbe S,Milligan G.CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer.Biochem J. 2008;412:245-56.
63. Ulbrich W,Lamprecht A.Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases.J R Soc Interface. 2010;7(Suppl 1):S55-66.
64. Pichai MV,Ferguson LR.Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.World J Gastroenterol. 2012;18:2895-901.
65. Ajuebor MN,Zagorski J,Kunkel SL,Strieter RM,Hogaboam CM.Contrasting roles for CXCR2 during experimental colitis.Exp Mol Pathol. 2004;76:1-8.
66. Belperio JA,Keane MP,Burdick MD,Gomperts B,Xue YY,Hong K,Mestas J,Ardehali A,Mehrad B,Saggar R,Lynch JP,Ross DJ,Strieter RM.Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome.J Clin Invest. 2005;115:1150-62.
67. Buanne P,Di Carlo E,Caputi L,Brandolini L,Mosca M,Cattani F,Pellegrini L,Biordi L,Coletti G,Sorrentino C,Fedele G,Colotta F,Melillo G,Bertini R.Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice.J Leukocyte Biol. 2007;82:1239-46.
68. Ness TL,Hogaboam CM,Strieter RM,Kunkel SL.Immunomodulatory role of CXCR2 during experimental septic peritonitis.J Immunol. 2003;171:3775-84.
69. Hall LR,Diaconu E,Patel R,Pearlman E.CXC chemokine receptor 2 but not C-C chemokine receptor 1 expression is essential for neutrophil recruitment to the cornea in helminth-mediated keratitis (river blindness).J Immunol. 2001;166:4035-41.
70. White JR,Lee JM,Young PR,Hertzberg RP,Jurewicz AJ,Chaikin MA, et al.Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration.J Biol Chem. 1998;273:10095-8.
71. Bento AF,Leite DF,Claudino RF,Hara DB,Leal PC,Calixto JB.The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice.J Leukocyte Biol. 2008;84:1213-21.
72. Bradley ME,Bond ME,Manini J,Brown Z,Charlton SJ.SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor.Br J Pharmacol. 2009;158:328-38.
73. Holz O,Khalilieh S,Ludwig-Sengpiel A,Watz H,Stryszak P,Soni P,Tsai M,Sadeh J,Magnussen H.SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.Eur Respir J. 2010;35:564-70.
74. Matzer SP,Zombou J,Sarau HM,Rollinghoff M,Beuscher HU.A synthetic, non-peptide CXCR2 antagonist blocks MIP-2-induced neutrophil migration in mice.Immunobiology. 2004;209:225-33.
75. Li JJ,Carson KG,Trivedi BK,Yue WS,Ye Q,Glynn RA,Miller SR,Connor DT,Roth BD,Luly JR,Low JE,Heilig DJ,Yang W,Qin S,Hunt S.Synthesis and structure-activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-molecule antagonists for interleukin-8 receptor.Bioorg Med Chem. 2003;11:3777-90.
76. Hayashi S,Yatsunami J,Fukuno Y,Kawashima M,Miller EJ.Antileukinate, a hexapeptide inhibitor of CXC-chemokine receptor, suppresses bleomycin-induced acute lung injury in mice.Lung. 2002;180:339-48.
77. Zarbock A,Allegretti M,Ley K.Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice.Br J Pharmacol. 2008;155:357-64.
78. Gorio A,Madaschi L,Zadra G,Marfia G,Cavalieri B,Bertini R, et al.Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord.J Pharmacol Exp Ther. 2007;322:973-81.
79. Garau A,Bertini R,Colotta F,Casilli F,Bigini P,Cagnotto A,Mennini T,Ghezzi P,Villa P.Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia.Cytokine. 2005;30:125-31.
80. Tazzyman S,Barry ST,Ashton S,Wood P,Blakey D,Lewis CE,Murdoch C.Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.Int J Cancer. 2011;129:847-58.
81. Chao J,Taveras AG,Chao J,Aki C,Dwyer M,Yu Y,Purakkattle B,Rindgen D,Jakway J,Hipkin W,Fosetta J,Fan XD,Lundell D,Fine J,Minnicozzi M,Phillips J,Merritt JR.C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.Bioorg Med Chem Lett. 2007;17:3778-83.
82. Winters MP,Crysler C,Subasinghe N,Ryan D,Leong L,Zhao S,Donatelli R,Yurkow E,Mazzulla M,Boczon L,Manthey CL,Molloy C,Raymond H,Murray L,McAlonan L,Tomczuk B.Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor.Bioorg Med Chem Lett. 2008;18:1926-30.
83. Garau A,Bertini R,Mosca M,Bizzarri C,Anacardio R,Triulzi S,Allegretti M,Ghezzi P,Villa P.Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.Eur Cytokine Network. 2006;17:35-41.
84. Lazaar AL,Sweeney LE,MacDonald AJ,Alexis NE,Chen C,Tal-Singer R.SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.Br J Clin Pharmacol. 2011;72:282-93.
85. Abu Nabah YN,Losada M,Estelles R,Mateo T,Company C,Piqueras L, et al.CXCR2 blockade impairs angiotensin II-induced CC chemokine synthesis and mononuclear leukocyte infiltration.Arteriosclerosis Thrombosis Vasc Biol. 2007;27:2370-6.
86. Zhao X,Li F,Town JR,Zhang X,Wang W,Gordon JR.Humanized forms of the CXCR1/CXCR2 antagonist, bovine CXCL8((3-74))K11R/G31P, effectively block ELR-CXC chemokine activity and airway endotoxemia pathology.Int Immunopharmacol. 2007;7:1723-31.
87. Podolin PL,Bolognese BJ,Foley JJ,Schmidt DB,Buckley PT,Widdowson KL,Jin Q,White JR,Lee JM,Goodman RB,Hagen TR,Kajikawa O,Marshall LA,Hay DW,Sarau HW.A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit.J Immunol. 2002;169:6435-44.
88. Pertuit D,Moulari B,Betz T,Nadaradjane A,Neumann D,Ismaili L,Refouvelet B,Pellequer Y,Lamprecht A.5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease.J Controlled Release. 2007;123:211-8.
89. Meissner Y,Pellequer Y,Lamprecht A.Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery.Int J Pharmaceutics. 2006;316:138-43.
90. Lamprecht A,Yamamoto H,Takeuchi H,Kawashima Y.Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats.J Pharmacol Exp Ther. 2005;315:196-202.
91. Lamprecht A,Ubrich N,Yamamoto H,Schafer U,Takeuchi H,Maincent P,Kawashima Y,Lehr CM.Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease.J Pharmacol Exp Ther. 2001;299:775-81.
92. Laroui H,Dalmasso G,Nguyen HT,Yan Y,Sitaraman SV,Merlin D.Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.Gastroenterology. 2010;138:843-53.e1-2.
93. Badawi AA,El-Laithy HM,El Qidra RK,El Mofty H,El dally M.Chitosan based nanocarriers for indomethacin ocular delivery.Arch Pharm Res. 2008;31:1040-9.
94. Catusse J,Liotard A,Loillier B,Pruneau D,Paquet JL.Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen alpha (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2.Biochem Pharmacol. 2003;65:813-21.
95. Bertini R,Allegretti M,Bizzarri C,Moriconi A,Locati M,Zampella G,Cervellera MN,Di Cioccio V,Cesta MC,Galliera E,Martinez FO,Di Bitondo R,Troiani G,Sabbatini V,D'Anniballe G,Anacardio R,Cutrin JC,Cavalieri B,Mainiero F,Strippoli R,Villa P,Di Girolamo M,Martin F,Gentile M,Santoni A,Corda D,Poli G,Mantovani A,Ghezzi P,Colotta F.Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.Proc Natl Acad Sci U S A. 2004;101:11791-6.
96. Bertini R,Barcelos LS,Beccari AR,Cavalieri B,Moriconi A,Bizzarri C,Di Benedetto P,Di Giacinto C,Gloaguen I,Galliera E,Corsi MM,Russo RC,Andrade SP,Cesta MC,Nano G,Aramini A,Cutrin JC,Locati M,Allegretti M,Teixeira MM.Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.Br J Pharmacol. 2012;165:436-54.
97. Wu Y,Wang S,Farooq SM,Castelvetere MP,Hou Y,Gao JL,Navarro JV,Oupicky D,Sun F,Li C.A chemokine receptor CXCR2 macromolecular complex regulates neutrophil functions in inflammatory diseases.J Biol Chem. 2012;287:5744-55.
98. Salchow K,Bond ME,Evans SC,Press NJ,Charlton SJ,Hunt PA,Bradley ME.A common intracellular allosteric binding site for antagonists of the CXCR2 receptor.Br J Pharmacol. 2010;159:1429-39.